ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Research findings likely to have significant implications for treatment of pre-eclampsia, hypertension

Scientists have discovered a mechanism which raises blood pressure in pre-eclampsia, a potentially deadly condition which occurs during pregnancy.

7 Oct 2010

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

DecImmune Therapeutics announced today that it has received a $1 million equity investment from Astellas Venture Management and has additionally been awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health.

28 Sep 2010

Researchers investigate performance levels of resident and staff physicians

Research on the quality of US resident physician performance levels has often been limited by lack of a comparison group or strict focus on specific diseases and geographical areas. In order to gain insight on differences in quality of care provided by resident physicians versus staff physicians, Boston Medical Center and Palo Alto Medical Foundation researchers investigated performance of physicians in 33,900 hospital-based outpatient visits throughout the US.

22 Sep 2010

Study finds no benefit from self-management counseling in patients with heart failure

Patients with mild to moderate heart failure who received educational materials and self-management counseling in an attempt to improve adherence to medical advice did not have a reduced rate of death or hospitalization compared to patients who received educational materials alone, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

Study on conflict between capacity to pay and need for health care

Cardiovascular disease (CVD) in all its forms is the biggest cause of death across Europe. Although there is little doubt that better focus on prevention can lessen its impact, we are left with a series of fundamental questions to what extent can the impact be reduced, and at what cost. And are the health benefits of prevention worth the investment. The EUROASPIRE III health economics study aims to find out.

31 Aug 2010

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.

31 Aug 2010

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.

31 Aug 2010

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

UNC Hospitals has received the American College of Cardiology Foundation's NCDR ACTION Registry-GWTG Silver Performance Achievement Award for 2010 - one of only 26 hospitals nationwide to do so.

26 Aug 2010

Study identifies four genetic variants associated with ESRD disease in Chinese diabetic patients

Examination of a gene involved in cell signaling finds that four common variants of this gene are associated with the development of end-stage renal disease in Chinese patients with type 2 diabetes, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Renin test can predict appropriate drugs for BP patients: Study

Commonly prescribed drugs used to lower blood pressure can actually have the opposite effect-raising blood pressure in a statistically significant percentage of patients. A new study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that doctors could avoid this problem-and select drugs most suitable for their patients-by measuring blood levels of the enzyme renin through a blood test that is becoming more widely available. The study appears in the online edition of the American Journal of Hypertension.

20 Aug 2010

Study examines comparative value of different blood pressure lowering medications

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.

13 Aug 2010

Study reveals link between allergies, asthma and old age

Mistaken for illnesses like bronchitis and emphysema, exacerbated by medications like aspirin, and overlooked by patients and doctors alike, asthma is a common and highly treatable condition in older adults. And while allergies tend to decrease with age, they also are frequently disregarded as a potential cause of misery for the elderly.

23 Jul 2010

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Data illustrates methods for improving adherence to medication, lowering prescription drug costs

CVS Caremark presented data at the 22nd Annual Meeting of the Academy of Managed Care Pharmacy that illustrate successful methods for improving adherence to medication and lowering prescription drug costs. The company showed results from three studies which demonstrated the positive impact of various tools available to pharmacy benefit managers – including automated telephonic messaging, fax alerts to physicians about gaps in care, and strategic co-pay waivers for generic medications.

8 Apr 2010

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

Millions of patients with high blood pressure and heart failure take a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. These drugs prevent the body from processing angiotensin II, a hormone that constricts blood vessels.

26 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say.

25 Feb 2010

ACE Inhibitors News and Research

Further Reading

Research findings likely to have significant implications for treatment of pre-eclampsia, hypertension

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

Researchers investigate performance levels of resident and staff physicians

Study finds no benefit from self-management counseling in patients with heart failure

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Study on conflict between capacity to pay and need for health care

ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

Study identifies four genetic variants associated with ESRD disease in Chinese diabetic patients

Renin test can predict appropriate drugs for BP patients: Study

Study examines comparative value of different blood pressure lowering medications

Study reveals link between allergies, asthma and old age

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

ARBs may be linked with increased risk of developing cancer: US scientists

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Data illustrates methods for improving adherence to medication, lowering prescription drug costs

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News